RecruitingPhase 4NCT05590637

Comparing Antipsychotic Medications in LBD Over Time

A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease


Sponsor

The University of Texas Health Science Center at San Antonio

Enrollment

94 participants

Start Date

Apr 22, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is comparing two antipsychotic medications — quetiapine and pimavanserin — in people with Lewy body dementia (LBD) or Parkinson's disease who are experiencing hallucinations or other psychotic symptoms. The goal is to find out which drug works better with fewer side effects over time. **You may be eligible if...** - You are a patient seen in a neurology clinic at UT Health San Antonio - You have been diagnosed with psychosis related to Parkinson's disease or Lewy body dementia - You need to start an antipsychotic medication for the first time - Your doctor is equally comfortable prescribing either quetiapine or pimavanserin **You may NOT be eligible if...** - You have a medical reason that prevents you from taking either medication - You are currently taking another antipsychotic drug - You do not have a caregiver available to complete symptom questionnaires Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPimavanserin

Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.

DRUGQuetiapine

Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.


Locations(2)

University Health System

San Antonio, Texas, United States

UT Health Science Center - San Antonio

San Antonio, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05590637


Related Trials